Market Sentiment - The CNN Money Fear and Greed index showed almost no change in overall market sentiment, remaining in the "Neutral" zone with a reading of 44.6, slightly down from 44.8 [5][6] Stock Performance - U.S. stocks settled mostly higher, with the Dow Jones index gaining around 319 points to close at 48,382.39. The S&P 500 increased by 0.19% to 6,858.47, while the Nasdaq Composite saw a slight decline of 0.03% to 23,235.63 [4] - Key chip stocks, including Nvidia and Micron Technology, experienced gains during the session [1] Annual Gains - In 2025, the S&P 500 surged by 16.39%, marking its third consecutive year of double-digit growth. The Nasdaq Composite gained 20.36%, while the Dow added 12.97% [2] Company-Specific News - Outlook Therapeutics, Inc. saw its shares drop over 58% after the FDA issued a complete response letter regarding its biologics license application for ONS-5010/LYTENAVA, indicating that the application cannot be approved in its current form [3]

Company Overview - Intelligent Bio Solutions Inc. (NASDAQ:INBS) announced plans to raise $10 million through a private placement, leading to a significant drop in its share price [1] - Following the announcement, shares of Intelligent Bio fell 19.7% to $7.65 [1] Stock Movements - Lavoro Limited (NASDAQ:LVRO) saw a substantial increase of 181%, reaching $1.2900 [4] - Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) rose 57.7% to $5.32 after issuing FY26 guidance, expecting US net sales of Linzess to be between $1.125 billion and $1.175 billion [4] - Brand Engagement Network, Inc. (NASDAQ:BNAI) jumped 56% to $3.6290 after entering a Vendor Services Project Agreement with a global advertising agency [4] - ChowChow Cloud International Holdings Limited (NYSE:CHOW) increased by 39.7% to $0.8500 due to year-over-year revenue and net income growth in H1 2025 [4] - Sidus Space, Inc. (NASDAQ:SIDU) gained 29% to $4.0314, marking a 470% surge over the past month [4] - Baidu, Inc. (NASDAQ:BIDU) rose 12.1% to $146.57 after announcing a proposed spin-off and Hong Kong listing of its AI unit [4] Declines - Outlook Therapeutics, Inc. (NASDAQ:OTLK) experienced a significant decline of 58% to $0.6632 after receiving a complete response letter from the FDA regarding its biologics license application [4] - ESH Acquisition Corp. (NASDAQ:ESHA) fell 23.5% to $14.68 [4] - Nuvve Holding Corp. (NASDAQ:NVVE) declined 15.3% to $2.1500 after announcing the closing of a private placement [4]

Market Performance - U.S. stocks showed mixed trading results, with the Dow Jones index increasing by 0.27% to 48,195.28, while the NASDAQ decreased by 0.14% to 23,209.54, and the S&P 500 fell by 0.01% to 6,845.25 [1] - Utilities shares rose by 0.8%, whereas consumer discretionary stocks declined by 1% [1] Economic Indicators - The S&P Global manufacturing PMI decreased to 51.8 in December from 52.2 in the previous month, indicating a slowdown in manufacturing activity [2][8] Commodity Prices - Oil prices fell by 1.3% to $56.67, while gold prices increased by 0.1% to $4,346.50. Silver saw a rise of 3% to $72.685, and copper rose by 0.1% to $5.6840 [5] European Market Trends - European shares mostly experienced gains, with the eurozone's STOXX 600 up by 0.60%, Spain's IBEX 35 Index rising by 0.83%, and London's FTSE 100 increasing by 0.32%. Germany's DAX slipped by 0.01%, while France's CAC 40 climbed by 0.29% [6] Asian Market Trends - Asian markets closed higher, with Hong Kong's Hang Seng Index surging by 2.76% and India's BSE Sensex gaining by 0.67% [7] Company-Specific Movements - ChowChow Cloud International Holdings Limited (NYSE:CHOW) shares surged by 29% to $0.78 following a year-over-year revenue and net income increase for H1 2025 [9] - Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares rose by 43% to $4.80 after issuing FY26 guidance [9] - AgEagle Aerial Systems, Inc. (NYSE:UAVS) shares increased by 35% to $1.10 after selling six tactical mapping drones to the U.S. Army [9] - Outlook Therapeutics, Inc. (NASDAQ:OTLK) shares dropped by 57% to $0.67 after receiving a complete response letter from the FDA regarding its biologics license application [9] - Intelligent Bio Solutions Inc (NASDAQ:INBS) shares fell by 19% to $7.74 due to plans for raising fresh capital [9] - Semilux International Ltd. (NASDAQ:SELX) shares decreased by 20% to $0.65 after receiving a Nasdaq delisting notification [9]

Market Overview - U.S. stocks showed mixed performance, with the Dow Jones index falling over 100 points, down 0.21% to 47,960.85, while NASDAQ decreased by 0.93% to 23,458.32. The S&P 500 rose by 0.36% to 6,870.03 [1] - Information technology shares increased by 1.5% on the same day [1] Sector Performance - Real estate stocks experienced a decline of 0.7% [2] Company News - Baidu Inc. (NASDAQ:BIDU) shares rose following the announcement of a proposed spinoff and separate listing of Kunlunxin (Beijing) Technology Co., Ltd. on the Hong Kong Stock Exchange [3] Commodity Market - Oil prices fell by 0.8% to $56.95, while gold prices increased by 0.9% to $4,380.20. Silver rose by 3.9% to $73.350, and copper saw a 0.5% increase to $5.7105 [6] Global Market Performance - European shares were up, with the eurozone's STOXX 600 gaining 0.6%, Spain's IBEX 35 Index rising 0.8%, and London's FTSE 100 increasing by 0.4% [7] - Asian markets closed higher, with Hong Kong's Hang Seng Index surging 2.76% and India's BSE Sensex gaining 0.67% [8] Company Stock Movements - ChowChow Cloud International Holdings Limited (NYSE:CHOW) shares surged 51% to $0.9364 after reporting year-over-year revenue and net income growth for H1 2025 [10] - Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares increased by 55% to $5.24 following the issuance of FY26 guidance [10] - AgEagle Aerial Systems, Inc. (NYSE:UAVS) shares rose by 31% to $1.0743 after selling six tactical mapping drones to the U.S. Army [10] - Outlook Therapeutics, Inc. (NASDAQ:OTLK) shares dropped 56% to $0.6801 after receiving a complete response letter from the FDA regarding its biologics license application [10] - Oriental Rise Holdings Limited (NASDAQ:ORIS) shares fell 18% to $1.22 [10] - Semilux International Ltd. (NASDAQ:SELX) shares decreased by 19% to $0.66 after receiving a Nasdaq delisting notification [10]

Core Viewpoint - U.S. stock futures are showing positive movement, particularly with Nasdaq 100 futures increasing by approximately 1% on Friday, while Outlook Therapeutics Inc faces significant stock decline due to FDA's response on its biologics license application [1]. Company Specifics - Outlook Therapeutics Inc (NASDAQ:OTLK) experienced a sharp decline of 60.9%, dropping to $0.62 in pre-market trading after the FDA issued a complete response letter regarding its ONS-5010/LYTENAVA application for treating wet age-related macular degeneration, indicating that the application cannot be approved in its current form [2][1]. - Intelligent Bio Solutions Inc (NASDAQ:INBS) saw a decrease of 19.2%, falling to $7.70 in pre-market trading following the announcement of a $10 million private placement priced at-the-market under Nasdaq rules [3]. - Net Lease Office Properties (NYSE:NLOP) shares dipped by 8.9% to $23.50 in pre-market trading [3]. - Progressive Corp (NYSE:PGR) tumbled by 5.8% to $214.60 in pre-market trading [3]. - Old Republic International Corp (NYSE:ORI) slipped by 4.8% to $43.42 in pre-market trading [3]. - Cango Inc – ADR (NYSE:CANG) fell by 4% to $1.44 in pre-market trading [3]. - Xeris Biopharma Holdings Inc (NASDAQ:XERS) decreased by 3.6% to $7.57 in pre-market trading after a previous gain of over 7% on Wednesday [3]. - Biohaven Ltd (NYSE:BHVN) fell by 2.6% to $11.00 in pre-market trading [3]. - RealReal Inc (NASDAQ:REAL) slipped by 2.3% to $15.41 in pre-market trading [3].

FDA Approvals & Rejections - ARS Pharma's neffy, a needle-free epinephrine nasal spray for emergency treatment of Type I allergic reactions, received approval in China, with commercial availability expected in spring 2026. The product generated $31.3 million in U.S. revenue in Q3 2025 [3][4]. - Vanda Pharmaceuticals' NEREUS, an oral NK-1 receptor antagonist for preventing motion-induced vomiting, received FDA approval, marking the first new treatment for motion sickness in over 40 years. The drug demonstrated a meaningful reduction in vomiting in clinical trials [5][6]. Clinical Trials - Breakthroughs & Setbacks - InflaRx's analyses from a halted Phase 3 trial of Vilobelimab in pyoderma gangrenosum indicated potential efficacy signals with longer treatment duration, prompting plans to discuss alternative endpoints with the FDA [15][17]. - SELLAS reported that survival in its Phase 3 REGAL trial for Galinpepimut-S (GPS) in acute myeloid leukaemia is extending longer than anticipated, potentially increasing the likelihood of a positive outcome [18][19]. - Ultragenyx announced that its Phase 3 studies for Setrusumab in Osteogenesis Imperfecta failed to meet primary endpoints, leading to a decline in investor confidence [20][21]. - Genmab decided to discontinue clinical development of Acasunlimab to focus on higher-priority programs, with no impact expected on its full-year 2025 financial guidance [22][23]. Corporate Actions - FONAR Corporation agreed to be taken private by a CEO-led acquisition group for $19.00 per share, valuing the transaction at a significant premium. The deal is expected to close in Q3 2026, subject to shareholder approval [12][13][14].

Company Developments - Baidu Inc announced a proposed spinoff and separate listing of the H shares of Kunlunxin (Beijing) Technology Co., Ltd on the Main Board of the Hong Kong Stock Exchange, leading to a 12.3% increase in Baidu's shares to $146.69 in pre-market trading [1] Stock Movements - Eason Technology Ltd surged 47.8% to $2.66 in pre-market trading after a previous decline of 10% [5] - Aimei Health Technology Co Ltd gained 32.8% to $85.01 after falling 22% on Wednesday [5] - Biofrontera Inc rose 28.5% to $0.73 following a dip of over 20% on Wednesday, after announcing the completion of FDA approvals for its products [5] - ChowChow Cloud International HLDG Ltd reported a revenue increase of 81.3% year-over-year to $22.8 million and net income growth of 80% to $1.6 million, resulting in a 26.8% rise in shares to $0.77 [5] - Rubico Inc increased 24.7% to $1.33 after announcing a purchase agreement for a vessel-owning company [5] - Sable Offshore Corp gained 21.4% to $10.96 after a 3% increase on Wednesday [5] - Diginex Ltd rose 17.8% to $4.91 after an 8% decline on Wednesday [5] - Sellas Life Sciences Group Inc gained 8.2% to $4.08 after a 14% increase on Wednesday [5] - X T L Biopharmaceuticals Ltd rose 8.1% to $0.63 after a decline of over 16% on Wednesday [5] Declines - Outlook Therapeutics Inc fell 60.9% to $0.62 after the FDA issued a complete response letter regarding its biologics license application [5] - Moolec Science SA declined 21.5% to $0.20 after receiving a determination letter from Nasdaq regarding stockholders' equity requirements [5] - Intelligent Bio Solutions Inc fell 19.2% to $7.70 following a $10 million private placement announcement [5] - Nocera Inc declined 9.7% to $0.77 in pre-market trading [5] - Nuvve Holding Corp dipped 9.3% to $2.30 after announcing the closing of a private placement [5] - Net Lease Office Properties shares dipped 8.9% to $23.50 [5] - Adlai Nortye Ltd fell 7.6% to $1.31 after a previous decline of around 5% [5] - Semilux International Ltd dipped 7.4% to $0.75 after a 14% increase on Wednesday [5] - Progressive Corp tumbled 5.8% to $214.60 [5] - Huachen AI Parking Mgmt Tech Hldg Co Ltd fell 5.3% to $0.33 after an 8% increase on Wednesday [5]

Company Updates - Apple Inc. has reduced production and marketing efforts for its Vision Pro headset due to disappointing sales, leading to a 0.5% decline in shares, closing at $271.86 [1] - Taiwan Semiconductor Manufacturing Co. has obtained a one-year U.S. export license to import chipmaking equipment into its China operations, resulting in a 2.3% increase in shares, closing at $1,585.00 [1] - VS Media Holdings Ltd. announced a 1-for-20 share combination, causing shares to surge by 17%, closing at $0.10 [1] - Outlook Therapeutics Inc. received a complete response letter from the FDA regarding its ONS-5010/LYTENAVA application, leading to a significant 63.3% drop in shares to $0.58 in after-hours trading [1] - Rubico Inc. has entered into a purchase agreement for acquiring a vessel-owning company linked to a shipbuilding contract for a mega yacht, resulting in a 40.2% increase in shares to $1.50 in after-hours trading [1]

Core Viewpoint - Outlook Therapeutics announced that the FDA issued a Complete Response Letter (CRL) regarding its BLA for ONS-5010/LYTENAVA™, indicating that the application for treating wet age-related macular degeneration (wAMD) cannot be approved in its current form [2][3]. Group 1: FDA Response and Company Position - The FDA's CRL stated that the additional data provided in the BLA did not alter the previous review conclusion, despite a well-controlled study demonstrating efficacy. The FDA recommended submitting confirmatory evidence to support the application but did not specify what type of evidence would be acceptable [3][8]. - The CEO of Outlook Therapeutics expressed disappointment with the FDA's decision but reaffirmed the company's commitment to obtaining approval in the U.S. and emphasized the clinical need and commercial potential for a specifically formulated bevacizumab product for intravitreal use [6][11]. Group 2: Clinical Trial Data - The resubmission of the BLA for ONS-5010 was based on the complete dataset from the NORSE clinical trial program, which included successful results from the NORSE TWO pivotal trial and additional safety and efficacy data from other NORSE trials [8]. - The NORSE TWO trial demonstrated significant efficacy, and the company believes that the complete dataset supports the BLA for approval in the U.S. [8]. Group 3: Market Expansion and Product Launch - LYTENAVA™ has received marketing authorization in the EU and the UK for treating wAMD, with plans to launch in Germany and the UK by June 2025 [11][19]. - The product is positioned as a cost-effective, first-line treatment option for healthcare professionals and patients, with potential gross peak sales exceeding $300 million across Germany and the UK, representing over 50% of the total opportunity in Western Europe [19][20].

Core Viewpoint - Micron Technology has shown significant investor interest, moving up 14 spots to 36th in Barchart's Top 100 Stocks to Buy, with a notable price volume of 6.53 million, indicating strong market activity [1][2]. Group 1: Stock Performance - Micron's stock has increased by 131.71% over the past 12 months, with a weighted alpha of 218.09, reflecting recent positive momentum [2]. - The stock price has risen 18% since November 20, suggesting bullish trends despite a recent 1.5% decline in a single trading day [2][4]. Group 2: Price Volume Analysis - Price volume is calculated as the stock's current price multiplied by its current volume divided by 1,000; for Micron, this resulted in a price volume of 6.53 million, significantly higher than the second-highest stock, IREN [3]. - A rising share price combined with increasing volume is considered a bullish indicator, although Micron's recent trading volume was 1.18 times its 20-day average [3]. Group 3: Market Sentiment - Despite a bearish signal from a 1.5% drop in stock price on a day of high volume, the overall trend since November 20 remains positive [4]. - The stock experienced a reversal with gains in 10 of the next 13 days, although on lighter-than-average volume, indicating potential waning enthusiasm among buyers [5].